Ana Vives‐Rodriguez
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ana Vives‐Rodriguez has a total of 38 co-authors. Here are the top co-authors by number of shared publications:
- Andrew E. Budson
Neurology Service, Veterans Affairs Boston Healthcare System, United States
3 shared publications - Anna Marin
Center for Translational Cognitive Neuroscience, VA Boston Healthcare System, Boston, MA, United States
3 shared publications - Katherine W. Turk
Center for Translational Cognitive Neuroscience, VA Boston Healthcare System
3 shared publications - Kylie A. Schiloski
VA Boston Healthcare System, Jamaica Plain, MA USA
3 shared publications Andrew Budson
VA Boston Healthcare System Jamaica Plain MA USA
2 shared publicationsAnna Marin
Center for Translational Cognitive Neuroscience VA Boston Healthcare System Boston Massachusetts USA
2 shared publications
Latest Publications
- Open Access
- 16 June 2023
- Published by Wiley in Alzheimer's & Dementia
- Vol. 19 (S2)
The association between electrophysiological and neuropsychological measures and cardiovascular disease in patients with Alzheimer’s Disease dementia
Background: Electrophysiological and neuropsychological measures are useful markers of Alzheimer’s Disease (AD); however, it is still unclear how these measures relate to the cardiovascular profile of AD patients, and their influence on disease progression and management. Our study examined how electrophysiological and neuropsychological measures are associated with cardiovascular risk factors and the severity of small vessel disease among patients with AD dementia.Method: Data were collected using a seven‐electrode COGNISION™ rig in 185 older veterans from the VA Boston Healthcare system memory disorders clinic. EEG/ERP data were recorded while participants completed a three‐tone auditory oddball task. All subjects were administered a neuropsychological battery composed of 8 subtests. Through review of medical history, we selected a subset of patients (N = 46) that met the following criteria: core clinical criteria for probable AD dementia, ≥ 65 years of age, and MMSE score between 20 and 26. We categorized these patients based on their number of cardiovascular risk factors—among hypertension, type 2 diabetes or prediabetes, hypercholesterolemia, and body mass index (BMI) ≥ 25 kg/m2 —and their small vessel disease severity (absent, mild, moderate, or severe). Spearman correlations were computed to assess the association of electrophysiological and neuropsychological measures with the number of cardiovascular risk factors and the severity of small vessel disease.Result: Alpha peak frequency was positively correlated with the number of cardiovascular risk factors (p = .011) and was inversely correlated with small vessel disease severity (p = .029). N100 standard latency was inversely correlated with small vessel disease severity (p = .018). Scores on the verbal phonemic fluency test were inversely correlated with the number of cardiovascular risk factors (p = .014), while scores on the verbal category fluency test were inversely correlated with small vessel disease severity (p = .023).Conclusion: Alpha peak frequency, N100, and verbal fluency scores are associated with the number of cardiovascular risk factors and small vessel disease severity in AD patients. Overall, these electrophysiological and neuropsychological measures represent a clinical tool to help characterize the cardiovascular profile of patients with AD dementia, and its contribution to overall disease progression.
- 16 June 2023
- Published by Wiley in Alzheimer's & Dementia
- Vol. 19 (S2)
Open AccessThe association between electrophysiological and neuropsychological measures and cardiovascular disease in patients with Alzheimer’s Disease dementia
Background: Electrophysiological and neuropsychological measures are useful markers of Alzheimer’s Disease (AD); however, it is still unclear how these measures relate to the cardiovascular profile of AD patients, and their influence on disease progression and management. Our study examined how electrophysiological and neuropsychological measures are associated with cardiovascular risk factors and the severity of small vessel disease among patients with AD dementia.Method: Data were collected using a seven‐electrode COGNISION™ rig in 185 older veterans from the VA Boston Healthcare system memory disorders clinic. EEG/ERP data were recorded while participants completed a three‐tone auditory oddball task. All subjects were administered a neuropsychological battery composed of 8 subtests. Through review of medical history, we selected a subset of patients (N = 46) that met the following criteria: core clinical criteria for probable AD dementia, ≥ 65 years of age, and MMSE score between 20 and 26. We categorized these patients based on their number of cardiovascular risk factors—among hypertension, type 2 diabetes or prediabetes, hypercholesterolemia, and body mass index (BMI) ≥ 25 kg/m2 —and their small vessel disease severity (absent, mild, moderate, or severe). Spearman correlations were computed to assess the association of electrophysiological and neuropsychological measures with the number of cardiovascular risk factors and the severity of small vessel disease.Result: Alpha peak frequency was positively correlated with the number of cardiovascular risk factors (p = .011) and was inversely correlated with small vessel disease severity (p = .029). N100 standard latency was inversely correlated with small vessel disease severity (p = .018). Scores on the verbal phonemic fluency test were inversely correlated with the number of cardiovascular risk factors (p = .014), while scores on the verbal category fluency test were inversely correlated with small vessel disease severity (p = .023).Conclusion: Alpha peak frequency, N100, and verbal fluency scores are associated with the number of cardiovascular risk factors and small vessel disease severity in AD patients. Overall, these electrophysiological and neuropsychological measures represent a clinical tool to help characterize the cardiovascular profile of patients with AD dementia, and its contribution to overall disease progression.
- Open Access
- 12 September 2022
- Published by JMIR Publications Inc. in JMIR Formative Research
- Vol. 6 (9) , e34450
Home-Based Electronic Cognitive Therapy in Patients With Alzheimer Disease: Feasibility Randomized Controlled Trial
Background: Can home-based computerized cognitive training programs be a useful tool to sustain cognition and quality of life in patients with Alzheimer disease (AD)? To date, the progressive nature of the disease has made this question difficult to answer. Computerized platforms provide more accessibility to cognitive trainings; however, the feasibility of long-term, home-based computerized programs for patients with AD dementia remains unclear. Objective: We aimed to investigate the feasibility of a 24-week home-based intervention program using the Constant Therapy app and its preliminary efficacy on cognition in patients with AD. Constant Therapy is a program developed for patients with speech and cognitive deficits. We hypothesized that patients with AD would use Constant Therapy daily over the course of the 24-week period. Methods: Data were collected over a 48-week period. We recruited participants aged between 50 and 90 years with a diagnosis of mild cognitive impairment due to AD or mild AD dementia. Participants were randomly assigned to either the Constant Therapy (n=10) or active control (n=9) group. The Constant Therapy group completed a tablet-based training during the first 24 weeks; the second 24 weeks of computerized training were optional. The active control group completed paper-and-pencil games during the first 24 weeks and were invited to complete an optional Constant Therapy training during the second 24 weeks. Every 6 weeks, the participants completed the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS). The participants independently accessed Constant Therapy using an Apple iPad. Our primary feasibility outcomes were the rate of adherence and daily use of Constant Therapy over 24 weeks. Our secondary outcomes were Constant Therapy performance over 24 weeks and change in RBANS scores between the 2 experimental groups. Results: Feasibility analyses were computed for participants who completed 24 weeks of Constant Therapy. We found that long-term use of the Constant Therapy program was feasible in patients with AD over 24 weeks (adherence 80%; program use 121/168 days, for 32 minutes daily). These participants showed an overall improvement in accuracy and latency (P=.005) in the Constant Therapy scores, as well as specific improvements in visual and auditory memory, attention, and arithmetic tasks. The Constant Therapy group showed improvement in the RBANS coding subtest. No unexpected problems or adverse events were observed. Conclusions: Long-term (eg, 24 weeks) computerized cognitive training using Constant Therapy is feasible in patients with AD in the mild cognitive impairment and mild dementia stages. Patients adhered more to Constant Therapy than to the paper-and-pencil training over 24 weeks and improved their performance over time. These findings support the development of future randomized controlled trials that will investigate the efficacy of Constant Therapy to sustain cognitive function in patients with AD. Trial Registration: ClinicalTrials.gov NCT02521558; https://clinicaltrials.gov/ct2/show/NCT02521558
- 12 September 2022
- Published by JMIR Publications Inc. in JMIR Formative Research
- Vol. 6 (9) , e34450
Open AccessHome-Based Electronic Cognitive Therapy in Patients With Alzheimer Disease: Feasibility Randomized Controlled Trial
Background: Can home-based computerized cognitive training programs be a useful tool to sustain cognition and quality of life in patients with Alzheimer disease (AD)? To date, the progressive nature of the disease has made this question difficult to answer. Computerized platforms provide more accessibility to cognitive trainings; however, the feasibility of long-term, home-based computerized programs for patients with AD dementia remains unclear. Objective: We aimed to investigate the feasibility of a 24-week home-based intervention program using the Constant Therapy app and its preliminary efficacy on cognition in patients with AD. Constant Therapy is a program developed for patients with speech and cognitive deficits. We hypothesized that patients with AD would use Constant Therapy daily over the course of the 24-week period. Methods: Data were collected over a 48-week period. We recruited participants aged between 50 and 90 years with a diagnosis of mild cognitive impairment due to AD or mild AD dementia. Participants were randomly assigned to either the Constant Therapy (n=10) or active control (n=9) group. The Constant Therapy group completed a tablet-based training during the first 24 weeks; the second 24 weeks of computerized training were optional. The active control group completed paper-and-pencil games during the first 24 weeks and were invited to complete an optional Constant Therapy training during the second 24 weeks. Every 6 weeks, the participants completed the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS). The participants independently accessed Constant Therapy using an Apple iPad. Our primary feasibility outcomes were the rate of adherence and daily use of Constant Therapy over 24 weeks. Our secondary outcomes were Constant Therapy performance over 24 weeks and change in RBANS scores between the 2 experimental groups. Results: Feasibility analyses were computed for participants who completed 24 weeks of Constant Therapy. We found that long-term use of the Constant Therapy program was feasible in patients with AD over 24 weeks (adherence 80%; program use 121/168 days, for 32 minutes daily). These participants showed an overall improvement in accuracy and latency (P=.005) in the Constant Therapy scores, as well as specific improvements in visual and auditory memory, attention, and arithmetic tasks. The Constant Therapy group showed improvement in the RBANS coding subtest. No unexpected problems or adverse events were observed. Conclusions: Long-term (eg, 24 weeks) computerized cognitive training using Constant Therapy is feasible in patients with AD in the mild cognitive impairment and mild dementia stages. Patients adhered more to Constant Therapy than to the paper-and-pencil training over 24 weeks and improved their performance over time. These findings support the development of future randomized controlled trials that will investigate the efficacy of Constant Therapy to sustain cognitive function in patients with AD. Trial Registration: ClinicalTrials.gov NCT02521558; https://clinicaltrials.gov/ct2/show/NCT02521558
- Open Access
- 17 August 2022
- Published by Wiley in Alzheimer's & Dementia: Translational Research & Clinical Interventions
- Vol. 8 (1) , e12320
Impact of amyloid PET in the clinical care of veterans in a tertiary memory disorders clinic
Introduction: We aimed to characterize the clinical impact of amyloid PET (APET) in a veteran population with cognitive decline by comparing differences in management between those who did and did not have an APET. Methods: This was a retrospective observational study. Poisson regressions and logistic regression were used for comparisons. Results: Out of 565 veterans, 197 underwent APET; positivity rate was 36.55%. Having an APET was associated with longer follow‐up, and increased diagnostic variability; it was not associated with number of additional studies, cholinesterase inhibitors prescription, or referrals to research. A positive APET was associated with less diagnostic variability, fewer additional tests, greater cholinesterase inhibitor prescriptions, and more research referrals. Discussion: In a medically complex, real‐world population, APET yielded lower positivity rates and was not associated with classical clinical utility variables when comparing patients with and without an APET. APET may be used more to “rule out” rather than to confirm Alzheimer's disease. Highlights: Amyloid PET was associated with longer follow‐up, and higher diagnostic variability. No association was seen with cholinesterase inhibitors prescription, or referrals to research. In complex patients, expected amyloid PET positivity rates are lower than previously described. Amyloid PETs were used to “rule out” AD than to confirm the diagnosis of AD.
- 17 August 2022
- Published by Wiley in Alzheimer's & Dementia: Translational Research & Clinical Interventions
- Vol. 8 (1) , e12320
Open AccessImpact of amyloid PET in the clinical care of veterans in a tertiary memory disorders clinic
Introduction: We aimed to characterize the clinical impact of amyloid PET (APET) in a veteran population with cognitive decline by comparing differences in management between those who did and did not have an APET. Methods: This was a retrospective observational study. Poisson regressions and logistic regression were used for comparisons. Results: Out of 565 veterans, 197 underwent APET; positivity rate was 36.55%. Having an APET was associated with longer follow‐up, and increased diagnostic variability; it was not associated with number of additional studies, cholinesterase inhibitors prescription, or referrals to research. A positive APET was associated with less diagnostic variability, fewer additional tests, greater cholinesterase inhibitor prescriptions, and more research referrals. Discussion: In a medically complex, real‐world population, APET yielded lower positivity rates and was not associated with classical clinical utility variables when comparing patients with and without an APET. APET may be used more to “rule out” rather than to confirm Alzheimer's disease. Highlights: Amyloid PET was associated with longer follow‐up, and higher diagnostic variability. No association was seen with cholinesterase inhibitors prescription, or referrals to research. In complex patients, expected amyloid PET positivity rates are lower than previously described. Amyloid PETs were used to “rule out” AD than to confirm the diagnosis of AD.
- Open Access
- 1 February 2022
- Published by Wiley in Alzheimer's & Dementia
- Vol. 17 (S7) , e054468
Associations between misinformation around COVID‐19 pandemic, severity of social isolation, and cognitive impairment
Background: In the past year, new research has focused on the degree of misinformation regarding the COVID‐19 pandemic in younger and older adults. However, no study has assessed how social isolation and cognitive status influence misinformation regarding the COVID‐19 pandemic. For this reason, we sought to investigate the differences in misinformation on the current pandemic in older individuals with and without cognitive impairment and social isolation in Boston, MA (United States) and Chieti (Italy).Method: Data has been obtained from 49 subjects from the Boston cohort and 138 from the Italian cohort. Both healthy older adults and individuals diagnosed with Mild Cognitive Impairment (MCI) or Alzheimer’s Disease (AD) Dementia were included. Cognitive status was assessed with a telephone administered neuropsychological battery and blind MoCA. Social isolation was evaluated with the Lubben social isolation scale and misinformation with a COVID‐19 Misinformation Questionnaire. Associations between these variables were assessed using Pearson correlation and binary logistic regression.Result: 35 participants in our sample (26%) met the cutoff for social isolation. 95 subjects (70%) were cognitively impaired. Subjects that were at a higher risk of being socially isolated were more cognitively impaired (r=0.43, N=181, p<.001). Also, they were less likely to know the correct age group that is most affected by the pandemic (b =0.06; p p<.001). Subjects that were more cognitively impaired were more likely to think that the COVID‐19 was a bioweapon developed by a government or terrorist organization (b =0.15; p <.001) and were more likely to incorrectly think that a person could not be COVID‐19 positive and be asymptomatic (b =0.17; p <.01). More analysis will be completed once recruitment is completed.Conclusion: Social isolation and cognitive impairment were associated with a higher degree of misinformation about COVID‐19 and less information about protective measures against infection, making patients with these characteristics a vulnerable population during the current pandemic.
- 1 February 2022
- Published by Wiley in Alzheimer's & Dementia
- Vol. 17 (S7) , e054468
Open AccessAssociations between misinformation around COVID‐19 pandemic, severity of social isolation, and cognitive impairment
Background: In the past year, new research has focused on the degree of misinformation regarding the COVID‐19 pandemic in younger and older adults. However, no study has assessed how social isolation and cognitive status influence misinformation regarding the COVID‐19 pandemic. For this reason, we sought to investigate the differences in misinformation on the current pandemic in older individuals with and without cognitive impairment and social isolation in Boston, MA (United States) and Chieti (Italy).Method: Data has been obtained from 49 subjects from the Boston cohort and 138 from the Italian cohort. Both healthy older adults and individuals diagnosed with Mild Cognitive Impairment (MCI) or Alzheimer’s Disease (AD) Dementia were included. Cognitive status was assessed with a telephone administered neuropsychological battery and blind MoCA. Social isolation was evaluated with the Lubben social isolation scale and misinformation with a COVID‐19 Misinformation Questionnaire. Associations between these variables were assessed using Pearson correlation and binary logistic regression.Result: 35 participants in our sample (26%) met the cutoff for social isolation. 95 subjects (70%) were cognitively impaired. Subjects that were at a higher risk of being socially isolated were more cognitively impaired (r=0.43, N=181, p<.001). Also, they were less likely to know the correct age group that is most affected by the pandemic (b =0.06; p p<.001). Subjects that were more cognitively impaired were more likely to think that the COVID‐19 was a bioweapon developed by a government or terrorist organization (b =0.15; p <.001) and were more likely to incorrectly think that a person could not be COVID‐19 positive and be asymptomatic (b =0.17; p <.01). More analysis will be completed once recruitment is completed.Conclusion: Social isolation and cognitive impairment were associated with a higher degree of misinformation about COVID‐19 and less information about protective measures against infection, making patients with these characteristics a vulnerable population during the current pandemic.
- 1 December 2021
- Published by Wiley in Alzheimer's & Dementia
- Vol. 17 (S4) , e053850
Use of amyloid PET scans in the clinical management of patients with cognitive decline in a naturalistic setting at a tertiary memory disorders clinic
Background: Amyloid PET(aPET) is used to aid differential diagnosis, increase diagnostic confidence and assist with management of patients with cognitive decline. In the United States, aPETs are not often used because they are costly and not covered by insurance. VA Boston Healthcare System provides a unique opportunity where aPETs are available for clinical purposes and are ordered to assist in the differential diagnosis of patients with cognitive decline when clinically relevant. This study aims to determine which factors are associated with the use of aPET for diagnostic confirmation of AD in a naturalistic setting at a tertiary memory disorders clinic and to determine which factors predict an abnormal result.Method: We conducted a retrospective review of all patients that were evaluated for cognitive decline at the Memory Disorders Clinic at Boston VA Medical Center from 9/2016 to 1/2020. Clinical information was extracted, including demographics, neuropsychological testing, and imaging studies. We compared patients' characteristics for whom an aPET was ordered and those for who a diagnosis was made without an aPET. We reviewed the characteristics of patients with positive vs. negative aPETResult: 565 patients were evaluated. 202 patients (35.75%) had an aPET as part of their workup; of these, 72 patients (36.5%) had an abnormal result. Factors associated with clinicians ordering the aPET were: younger age, longer clinical course, absence of amyloid angiopathy on MRI, and a diagnosis of mild cognitive impairment (MCI) and mild dementia. When performing multivariate analysis of the clinical characteristics, imaging, and neuropsychological tests of patients, only a positive family history of dementia (p=0.004) and presence of false‐positives on recognition in the CERAD list learning task (p=0.004) were associated with an abnormal result.Conclusion: In this cohort, aPETs were ordered in younger patients who fulfilled the criteria for MCI and mild dementia, and had a longer clinical course. Only a family history of dementia and false‐positives on recognition during a list learning task were significantly associated with an abnormal result. The results of this study may be informative both regarding how aPET may be used if covered by insurance and regarding clues to determining underlying Alzheimer’s pathology without biomarkers.
- 1 December 2021
- Published by Wiley in Alzheimer's & Dementia
- Vol. 17 (S4) , e053850
Use of amyloid PET scans in the clinical management of patients with cognitive decline in a naturalistic setting at a tertiary memory disorders clinic
Background: Amyloid PET(aPET) is used to aid differential diagnosis, increase diagnostic confidence and assist with management of patients with cognitive decline. In the United States, aPETs are not often used because they are costly and not covered by insurance. VA Boston Healthcare System provides a unique opportunity where aPETs are available for clinical purposes and are ordered to assist in the differential diagnosis of patients with cognitive decline when clinically relevant. This study aims to determine which factors are associated with the use of aPET for diagnostic confirmation of AD in a naturalistic setting at a tertiary memory disorders clinic and to determine which factors predict an abnormal result.Method: We conducted a retrospective review of all patients that were evaluated for cognitive decline at the Memory Disorders Clinic at Boston VA Medical Center from 9/2016 to 1/2020. Clinical information was extracted, including demographics, neuropsychological testing, and imaging studies. We compared patients' characteristics for whom an aPET was ordered and those for who a diagnosis was made without an aPET. We reviewed the characteristics of patients with positive vs. negative aPETResult: 565 patients were evaluated. 202 patients (35.75%) had an aPET as part of their workup; of these, 72 patients (36.5%) had an abnormal result. Factors associated with clinicians ordering the aPET were: younger age, longer clinical course, absence of amyloid angiopathy on MRI, and a diagnosis of mild cognitive impairment (MCI) and mild dementia. When performing multivariate analysis of the clinical characteristics, imaging, and neuropsychological tests of patients, only a positive family history of dementia (p=0.004) and presence of false‐positives on recognition in the CERAD list learning task (p=0.004) were associated with an abnormal result.Conclusion: In this cohort, aPETs were ordered in younger patients who fulfilled the criteria for MCI and mild dementia, and had a longer clinical course. Only a family history of dementia and false‐positives on recognition during a list learning task were significantly associated with an abnormal result. The results of this study may be informative both regarding how aPET may be used if covered by insurance and regarding clues to determining underlying Alzheimer’s pathology without biomarkers.
- Open Access
- 14 June 2021
- Published by Frontiers Media SA in Frontiers in Neurology
- Vol. 12
Head Injury Exposure in Veterans Presenting to Memory Disorders Clinic: An Observational Study of Clinical Characteristics and Relationship of Event-Related Potentials and Imaging Markers
Objective: Traumatic brain injury (TBI) and repetitive head impacts (RHI) related to blasts or contact sports are commonly reported among military service members. However, the clinical implications of remote TBI and RHI in veterans remains a challenge when evaluating older veterans at risk of neurodegenerative conditions including Alzheimer's disease (AD) and Chronic Traumatic Encephalopathy (CTE). This study aimed to test the hypothesis that veterans in a memory disorders clinic with remote head injury would be more likely to have neurodegenerative clinical diagnoses, increased rates of amyloid PET positivity, higher prevalence of cavum septum pellucidi/vergae, and alterations in event-related potential (ERP) middle latency auditory evoked potentials (MLAEPs) and long latency ERP responses compared to those without head injuries.Methods: Older veterans aged 50–100 were recruited from a memory disorders clinic at VA Boston Healthcare system with a history of head injury (n = 72) and without head injury history (n = 52). Patients were classified as reporting prior head injury including TBI and/or RHI exposure based on self-report and chart review. Participants underwent MRI to determine presence/absence of cavum and an ERP auditory oddball protocol.Results: The head injury group was equally likely to have a positive amyloid PET compared to the non-head injury group. Additionally, the head injury group were less likely to have a diagnosis of a neurodegenerative condition than those without head injury. P200 target amplitude and MLAEP amplitudes for standard and target tones were decreased in the head injury group compared to the non-head injury group while P3b amplitude did not differ.Conclusions: Veterans with reported remote head injury evaluated in a memory disorders clinic were not more likely to have a neurodegenerative diagnosis or imaging markers of neurodegeneration than those without head injury. Decreased P200 target and MLAEP target and standard tone amplitudes in the head injury group may be relevant as potential diagnostic markers of remote head injury.
- 14 June 2021
- Published by Frontiers Media SA in Frontiers in Neurology
- Vol. 12
Open AccessHead Injury Exposure in Veterans Presenting to Memory Disorders Clinic: An Observational Study of Clinical Characteristics and Relationship of Event-Related Potentials and Imaging Markers
Objective: Traumatic brain injury (TBI) and repetitive head impacts (RHI) related to blasts or contact sports are commonly reported among military service members. However, the clinical implications of remote TBI and RHI in veterans remains a challenge when evaluating older veterans at risk of neurodegenerative conditions including Alzheimer's disease (AD) and Chronic Traumatic Encephalopathy (CTE). This study aimed to test the hypothesis that veterans in a memory disorders clinic with remote head injury would be more likely to have neurodegenerative clinical diagnoses, increased rates of amyloid PET positivity, higher prevalence of cavum septum pellucidi/vergae, and alterations in event-related potential (ERP) middle latency auditory evoked potentials (MLAEPs) and long latency ERP responses compared to those without head injuries.Methods: Older veterans aged 50–100 were recruited from a memory disorders clinic at VA Boston Healthcare system with a history of head injury (n = 72) and without head injury history (n = 52). Patients were classified as reporting prior head injury including TBI and/or RHI exposure based on self-report and chart review. Participants underwent MRI to determine presence/absence of cavum and an ERP auditory oddball protocol.Results: The head injury group was equally likely to have a positive amyloid PET compared to the non-head injury group. Additionally, the head injury group were less likely to have a diagnosis of a neurodegenerative condition than those without head injury. P200 target amplitude and MLAEP amplitudes for standard and target tones were decreased in the head injury group compared to the non-head injury group while P3b amplitude did not differ.Conclusions: Veterans with reported remote head injury evaluated in a memory disorders clinic were not more likely to have a neurodegenerative diagnosis or imaging markers of neurodegeneration than those without head injury. Decreased P200 target and MLAEP target and standard tone amplitudes in the head injury group may be relevant as potential diagnostic markers of remote head injury.
- 24 May 2019
- Published by Elsevier
- p. 209-215
Symptomatic Treatment of Residual Neurological or Psychiatric Disease
- 24 May 2019
- Published by Elsevier
- p. 209-215
Symptomatic Treatment of Residual Neurological or Psychiatric Disease